Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2022

View Archived Issues

Discovery of potent tubulin polymerization inhibitor with promising anticancer activity

Novel immune-competent mouse model of acute myeloid leukemia

Code Biotherapeutics raises series A financing to advance programs for genetic diseases

PineTree Therapeutics to advance oncology and viral diseases platforms

Biogen and Alectos enter license and collaboration agreement for GBA2 inhibitor for Parkinson's

Southern Research Institute and UABRF report development of HO-1 modulators

University of California and University of Washington divulge IRE1 inhibitors

Foghorn Therapeutics describes SNF2L2/BRG1 inhibitors

Janssen Pharmaceutica discloses MAP3K14 inhibitors

Korean research groups patent novel antioxidants

Prognostic biomarkers of atherosclerosis and cardiovascular disease in patients with SLE

CiPA used to validate Axol's iPSC-derived ventricular cardiomyocytes for cardiac safety testing

Find Therapeutics and SATT Conectus sign licensing agreement for new approach to treat MS

Targeting NLRP3 inflammasome pathway prevents C. septicum-induced lethality

Kiromic enters SRA with MD Anderson to support IND filings for gamma delta T-cell product candidates

Coya raises financing to advance Treg-derived exosome therapeutics into clinic

WNT plays dual role in melanoma spread to lung

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...